Crescent Biopharma (CBIO) Receivables - Net (2015 - 2025)

Crescent Biopharma (CBIO) reported Receivables - Net of $18.0 million for Q4 2025, down 10.0% quarter-over-quarter from $20.0 million in Q2 2015.

Crescent Biopharma (CBIO) Receivables - Net (2015 - 2025) Analysis & Trends

Crescent Biopharma (CBIO) has 2 years of Receivables - Net data on file, last reported at $18.0 million in Q4 2025.

Receivables - Net for Q4 2025 came in at $18.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $18.0 million (changed N/A YoY), and the FY2025 annual result was $18.0 million, changed N/A from the prior year.
Receivables - Net eased to $18.0 million in Q4 2025 per CBIO's latest filing, from $20.0 million in the prior quarter.
Over five years, Receivables - Net peaked at $18.0 million in Q4 2025 and troughed at $18.0 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Crescent Biopharma	486.92 Mn	297.76 Mn	-

Download Data